Free Daily Biotech Industry Newsletter
Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 150,000 biotech professionals who subscribe to FierceBiotech for FREE!
After years of FDA chidings and resultant drug shortages, Boehringer Ingelheim is pulling the plug on its Ben Venue contract manufacturing business by the end of the year, planning to lay off 1,100 workers. Article
| Wednesday, July 22nd | 11am ET / 8am PT | Sponsored by: UPS
Biopharma companies can never eliminate the risk of supply chain disruption, but they can prevent some problems and prepare themselves for others. Knowing every company in the supply chain--from tier one down--and having contingency plans in place are essential steps to foreseeing and responding to disruptions. Maps of supply chain risks give companies this knowledge. Register Now!
FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!